INT144302

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.86
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 9
Disease Relevance 7.43
Pain Relevance 3.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (MMP3) extracellular space (MMP3) extracellular region (MMP3)
proteinaceous extracellular matrix (MMP3) nucleus (MMP3) protein complex (MMP3)
Anatomy Link Frequency
cartilage 5
synovial fluid 3
joints 1
MMP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 39 100.00 Very High Very High Very High
Osteoarthritis 362 99.84 Very High Very High Very High
Pain 201 99.12 Very High Very High Very High
Inflammation 105 98.44 Very High Very High Very High
Inflammatory response 7 98.44 Very High Very High Very High
Pain score 72 97.80 Very High Very High Very High
Bioavailability 6 84.56 Quite High
spinal inflammation 58 82.48 Quite High
cytokine 25 57.20 Quite High
abdominal pain 4 57.16 Quite High
Disease Link Frequency Relevance Heat
Osteoarthritis 362 99.84 Very High Very High Very High
Pain 266 99.12 Very High Very High Very High
INFLAMMATION 125 98.44 Very High Very High Very High
Disease 32 98.44 Very High Very High Very High
Low Back Pain 59 90.00 High High
Chromosome Aberrations 3 82.28 Quite High
Arthritis 18 79.68 Quite High
Viral Infection 4 77.56 Quite High
Osteoporosis 3 72.88 Quite High
Toxicity 7 62.16 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We also explored the effect of 5-Loxin® on the cartilage degrading enzyme MMP-3 in OA patients treated with 5-Loxin®.


Protein_catabolism (degrading) of MMP-3 in cartilage associated with osteoarthritis
1) Confidence 0.86 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575633 Disease Relevance 0.89 Pain Relevance 0.40
A novel aspect of the present study is its evaluation of the effect of 5-Loxin® treatment on the cartilage degrading enzyme MMP-3 in synovial fluid from OA patients.
Protein_catabolism (degrading) of MMP-3 in synovial fluid associated with osteoarthritis
2) Confidence 0.86 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575633 Disease Relevance 1.26 Pain Relevance 0.67
MMP-3 degrades extracellular matrix proteins and is involved in disruptive events in the cartilage and bone of inflamed joints [15].
Protein_catabolism (degrades) of MMP-3 in joints
3) Confidence 0.75 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592815 Disease Relevance 1.10 Pain Relevance 0.44
Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients.
Protein_catabolism (degrading) of matrix metalloproteinase-3 in synovial fluid associated with metalloproteinase and osteoarthritis
4) Confidence 0.65 Published 2008 Journal Arthritis Res Ther Section Abstract Doc Link PMC2575633 Disease Relevance 0.95 Pain Relevance 0.64
In summary, the present study provides the evidence in support of the potential efficacy and safety of 5-Loxin® in patients with OA: 5-Loxin® significantly improved joint function and exhibited better therapeutic efficacy at 250 mg/day than at 100 mg/day; it reduces pain rapidly, as early as after 1 week of treatment; it reduces levels of the cartilage degrading enzyme MMP-3 in synovial fluid; and, most importantly, 5-Loxin® is safe for human consumption, even long term.
Protein_catabolism (degrading) of MMP-3 in synovial fluid associated with pain and osteoarthritis
5) Confidence 0.57 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2575633 Disease Relevance 0.69 Pain Relevance 0.39
These biomarkers were cartilage oligomeric matrix protein, human cartilage gp-39 (YKL-40), type II collagen epitopes detected by the C2C and C1,2C degradation assays and the CPII synthesis assay, aggrecan 846 epitope, osteoprotegerin, and matrix metalloproteinase 3 (MMP-3).
Protein_catabolism (degradation) of MMP-3 in cartilage
6) Confidence 0.56 Published 2007 Journal Arthritis Rheum. Section Body Doc Link 17530713 Disease Relevance 0.18 Pain Relevance 0
The dose dependent efficacy of 5-Loxin® was assessed against pain, joint stiffness, mobility and a cartilage degrading enzyme MMP-3 in OA subjects 22.
Protein_catabolism (degrading) of MMP-3 in cartilage associated with pain and osteoarthritis
7) Confidence 0.47 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2974165 Disease Relevance 0.72 Pain Relevance 0.36
Furthermore, in vitro studies also provide evidences that compared to 5-Loxin, Aflapin is capable of inhibiting cartilage degrading enzyme MMP-3 and has the potential to regulate the inflammatory component in by inhibiting ICAM-1.
Protein_catabolism (degrading) of MMP-3 in cartilage associated with inflammation
8) Confidence 0.47 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2974165 Disease Relevance 0.62 Pain Relevance 0.38
Corroborating the improvements in pain scores in treatment groups, our in vitro studies provide evidences that Aflapin® is capable of inhibiting cartilage degrading enzyme MMP-3 and has the potential to regulate the inflammatory response by inhibiting ICAM-1.
Protein_catabolism (degrading) of MMP-3 in cartilage associated with inflammatory response and pain score
9) Confidence 0.47 Published 2010 Journal International Journal of Medical Sciences Section Abstract Doc Link PMC2974165 Disease Relevance 1.01 Pain Relevance 0.72

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox